

offenses he pled guilty to, including the offenses of: (1) importation into the United States a quantity of ethylone, a Schedule I Controlled Substance in violation of 21 U.S.C. 952(a) and 960(a)(1); (2) importation into the United States quantities of TURINABOL and DIANABOL, anabolic steroids, and Schedule III Controlled Substances in violation of 21 U.S.C. 952(b) and 960(a)(1); and (3) smuggling goods into the United States, that is, alpha-PVP ethylone, Schedule I Controlled Substances, and TURINBOL and DIANABOL, Schedule III Controlled Substances, in violation of 18 U.S.C. 545. FDA's finding that debarment is appropriate is based on the felony conviction referenced herein. The factual basis for this conviction is as follows:

As contained in the superseding indictment, filed on March 22, 2018, the Defendant's motion for downward variance, filed on April 24, 2023, and the Government's sentencing memorandum, filed April 24, 2023, from Mr. Nagy's case, Mr. Nagy was the owner and operator of Prescription Nutrition, Prescription Protein, and N.O.B. Industries located in Pennsylvania. From on or about June 2014 to on or about September 2014, Mr. Nagy imported various types of controlled substances which he then capsuled and distributed to clients. Specifically, from on or about June 2014 to on or about July 2014, Mr. Nagy illegally imported ethylone. In July 2014, he also illegally imported TURINABOL and DIANABOL. In addition, from June 2014 until on or about September 2014, Mr. Nagy illegally imported alpha-PVP, ethylone, TURINABOL, and DIANABOL. All the controlled substances Mr. Nagy imported and smuggled into the country came from China.

As a result of this conviction, FDA sent Mr. Nagy, by certified mail, on September 20, 2023, a notice proposing to debar him for a 15-year period from importing or offering for import any drug into the United States. The proposal was based on a finding under section 306(b)(3)(C) of the FD&C Act that Mr. Nagy's three felony convictions that included: (1) importation into the United States a quantity of ethylone, a Schedule I Controlled Substance in violation of 21 U.S.C. 952(a) and 960(a)(1); (2) importation into the United States quantities of TURINABOL and DIANABOL, anabolic steroids and Schedule III Controlled Substances in violation of 21 U.S.C. 952(b) and 960(a)(1); and (3) smuggling goods into the United States, that is, alpha-PVP ethylone, Schedule I Controlled

Substances, and TURINBOL, DIANABOL, Schedule III Controlled Substances in violation of 18 U.S.C. 545, were for conduct relating to the importation into the United States of any drug or controlled substance because he imported controlled substances into the United States in order to capsule portions of the drugs to sell to clients. In proposing a debarment period, FDA weighed the considerations set forth in section 306(c)(3) of the FD&C Act that it considered applicable to Mr. Nagy's offenses and concluded that each offense warranted the imposition of a 5-year period of debarment, to run consecutively, for a total of a 15-year period of debarment.

The proposal informed Mr. Nagy of the proposed debarment and offered him an opportunity to request a hearing, providing him 30 days from the date of receipt of the letter in which to file the request, and advised him that failure to request a hearing constituted a waiver of the opportunity for a hearing and of any contentions concerning this action. Mr. Nagy received the proposal and notice of opportunity for a hearing on September 22, 2023. Mr. Nagy failed to request a hearing within the timeframe prescribed by regulation and has, therefore, waived his opportunity for a hearing and waived any contentions concerning his debarment (21 CFR part 12).

## II. Findings and Order

Therefore, the Assistant Commissioner, Office of Human and Animal Food Operations, under section 306(b)(3)(C) of the FD&C Act, under authority delegated to the Assistant Commissioner, finds that Adam Michael Nagy been convicted of three felonies under federal law for conduct relating to the importation into the United States of any drug or controlled substance. FDA finds that the offense should be accorded a debarment period of 15 years as provided by section 306(c)(2)(A)(iii) of the FD&C Act.

As a result of the foregoing finding, Mr. Nagy is debarred for a period of 15 years from importing or offering for import any drug into the United States, effective (see DATES). Pursuant to section 301(cc) of the FD&C Act (21 U.S.C. 331(cc)), the importing or offering for import into the United States of any drug by, with the assistance of, or at the direction of Mr. Nagy is a prohibited act.

Dated: December 11, 2023.

**Lauren K. Roth,**

*Associate Commissioner for Policy.*

[FR Doc. 2023-27557 Filed 12-14-23; 8:45 am]

**BILLING CODE 4164-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Health Resources and Services Administration

#### Meeting of the National Advisory Council on Nurse Education and Practice

**AGENCY:** Health Resources and Services Administration, Department of Health and Human Services.

**ACTION:** Notice.

**SUMMARY:** In accordance with the Federal Advisory Committee Act, this notice announces that the National Advisory Council on Nurse Education and Practice (NACNEP) will hold public meetings for the 2024 calendar year (CY). Information about NACNEP, agendas, and materials for these meetings can be found on the NACNEP website at <https://www.hrsa.gov/advisory-committees/nursing>.

**DATES:** NACNEP meetings will be on (all in Eastern Time):

- March 14, 2024, 10 a.m.–4 p.m. and March 15, 2024, 10 a.m.–4 p.m.;
- May 9, 2024, 10 a.m.–4 p.m.;
- August 7, 2024, 10 a.m.–4 p.m. and August 8, 2024, 10 a.m.–4 p.m.; and
- December 5, 2024, 8 a.m.–5 p.m. and December 6, 2024, 8 a.m.–2 p.m.

**ADDRESSES:** Meetings may be held in person, via teleconference, and/or video conference. In-person meetings will be held at 5600 Fishers Lane, Rockville, Maryland 20857. For updates on how the meeting will be held and instructions for joining meetings, visit the NACNEP website at <https://www.hrsa.gov/advisory-committees/nursing/meetings> 14 business days before the date of the meeting.

**FOR FURTHER INFORMATION CONTACT:** Justin Bala-Hampton, Designated Federal Official, NACNEP, Bureau of Health Workforce, Division of Nursing and Public Health, Health Resources and Services Administration, 5600 Fishers Lane, 11N100D, Rockville, Maryland 20857; 301-443-5260; or [jbala-hampton@hrsa.gov](mailto:jbala-hampton@hrsa.gov).

**SUPPLEMENTARY INFORMATION:** NACNEP provides advice and recommendations to the Secretary of Health and Human Services on policy, program development, and other matters of significance concerning the activities under title VIII of the Public Health Service Act, including the range of issues relating to the nurse workforce, education, and practice improvement. NACNEP also prepares and submits an annual report to the Secretary of Health and Human Services and Congress describing its activities, including

NACNEP's findings and recommendations concerning activities under Title VIII, as required by the Public Health Service Act.

Since priorities dictate meeting times, be advised that times and agenda items are subject to change. For CY 2024 meetings, agenda items may include, but are not limited to, the nursing workforce (e.g., nursing shortage, distribution, supply, and access) nursing practice improvement, nursing education, nursing work environment and support, and other Title VIII program activities. Refer to the NACNEP website listed above for all current and updated information concerning the CY 2024 NACNEP meetings. Agendas and meeting materials that will be posted up to 30 calendar days but no later 14 calendar days before the meeting.

Members of the public will have the opportunity to provide comments. Public participants may submit written statements in advance of the scheduled meeting(s). Oral comments will be honored in the order they are requested and may be limited as time allows. Requests to submit a written statement or make oral comments to NACNEP should be sent to Justin Bala-Hampton using the contact information above at least 5 business days before the meeting.

Individuals who need special assistance or another reasonable accommodation should notify Justin Bala-Hampton at the email address and phone number listed above at least 10 business days before the meeting(s) they wish to attend. In-person meetings occur in a federal government building, and attendees must pass a security check to enter the building. Non-U.S. citizen attendees must notify Justin Bala-Hampton of their planned attendance at least 20 business days prior to the meeting to facilitate their entry into the building. All attendees are required to present government-issued identification prior to entry.

**Maria G. Button,**

*Director, Executive Secretariat.*

[FR Doc. 2023-27618 Filed 12-14-23; 8:45 am]

**BILLING CODE 4165-15-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Health Resources and Services Administration

#### Meeting of the Council on Graduate Medical Education

**AGENCY:** Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS).

**ACTION:** Notice.

**SUMMARY:** In accordance with the Federal Advisory Committee Act, this notice announces that the Council on Graduate Medical Education (COGME or Council) will hold public meetings for the 2024 calendar year (CY). Information about COGME, agendas, and materials for these meetings can be found on the COGME website at <https://www.hrsa.gov/advisory-committees/graduate-medical-edu/meetings>.

**DATES:** COGME meetings will be held on:

- March 4, 2024, 9:00 a.m.–5:00 p.m. Eastern Time (ET) and March 5, 2024, 9:00 a.m.–2:00 p.m. ET; and
- September 12, 2024, 10:00 a.m.–5:00 p.m. ET and September 13, 2024, 10:00 a.m.–3:00 p.m. ET.

**ADDRESSES:** The meeting scheduled for March 2024 will be held in-person at 5600 Fishers Lane, Rockville, Maryland 20857. The meeting scheduled for September 2024 will be held remotely by teleconference/webinar. The meeting format is subject to change as needed. For any updates on how the meetings will be held, visit the COGME website 30 business days before the date of the meeting, where instructions for joining meetings will be posted. For meeting information updates, go to the COGME website meeting page at <https://www.hrsa.gov/advisory-committees/graduate-medical-edu/meetings>.

**FOR FURTHER INFORMATION CONTACT:** Dr. Curi Kim, Designated Federal Official, Division of Medicine and Dentistry, Bureau of Health Workforce, HRSA, 5600 Fishers Lane, Room 15N35, Rockville, Maryland 20857; 301-945-5827; or [CKim@hrsa.gov](mailto:CKim@hrsa.gov).

**SUPPLEMENTARY INFORMATION:** COGME provides advice and recommendations to the Secretary of HHS and Congress on policy, program development, and other matters of significance regarding the issues listed in section 762(a)(1) of the Public Health Service Act. Issues addressed by the COGME include the supply and distribution of the physician workforce in the United States, including any projected shortages or excesses; international medical graduates; the nature and financing of undergraduate and graduate medical education; appropriation levels for certain programs under Title VII of the Public Health Service Act; and deficiencies in databases concerning the supply and distribution of the physician workforce and postgraduate programs for training physicians. COGME submits reports to the Secretary of HHS; the Senate Committee on Health, Education, Labor and Pensions; and the House of

Representatives Committee on Energy and Commerce. Additionally, COGME encourages entities providing graduate medical education to conduct activities to voluntarily achieve the recommendations of the Council related to appropriate efforts to be carried out by hospitals, schools of medicine, schools of osteopathic medicine, and accrediting bodies with respect to the supply and distribution of physicians in the United States; current and future shortages or excesses of physicians in medical and surgical specialties and subspecialties; and issues relating to international medical graduates, including efforts for changes in undergraduate and graduate medical education programs.

Since priorities dictate meeting times, be advised that start times, end times, and agenda items are subject to change. For CY 2024 meetings, agenda items may include, but are not limited to, discussions on team-based care, graduate medical education data, and the topic areas listed above. Refer to the COGME website listed above for all current and updated information concerning the CY 2024 COGME meetings, including draft agendas and meeting materials that will be posted 30 calendar days before the meeting.

Members of the public will have the opportunity to provide comments. Public participants may submit written statements in advance of the scheduled meeting(s). Oral comments will be honored in the order they are requested and may be limited as time allows. Requests to submit a written statement or make oral comments to COGME should be sent to Dr. Kim using the contact information above at least 5 business days before the meeting date(s).

Individuals who need special assistance or another reasonable accommodation should notify Dr. Kim using the contact information listed above at least 10 business days before the meeting(s) they wish to attend. Since all in-person meetings occur in a federal government building, attendees must go through a security check to enter the building. Non-U.S. Citizen attendees must notify HRSA of their planned attendance at least 20 business days prior to the meeting in order to facilitate their entry into the building. All attendees are required to present government-issued identification prior to entry.

**Maria G. Button,**

*Director, Executive Secretariat.*

[FR Doc. 2023-27500 Filed 12-14-23; 8:45 am]

**BILLING CODE 4165-15-P**